Advertisement
Advertisement
FEMY
Femasys Inc. Common Stock
0.52
USDSponsored
+0.03
+6.19%
Feb 06, 15:59 UTC -5
Closed
After-Market
0.51
-0.01
-0.97%
FEMY Earnings Reports
Positive Surprise Ratio
FEMY beat 8 of 17 last estimates.
47%
Next Report
Date of Next Report
Mar 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.46M
/-$0.09
Implied change from Q3 25 (Revenue/ EPS)
+99.62%
/-10.00%
Implied change from Q4 24 (Revenue/ EPS)
+150.03%
/-60.87%
Femasys Inc. Common Stock earnings per share and revenue
On Nov 14, 2025, FEMY reported earnings of -0.10 USD per share (EPS) for Q3 25, beating the estimate of -0.13 USD, resulting in a 24.59% surprise. Revenue reached 729.00 thousand, compared to an expected 1.48 million, with a -50.71% difference. The market reacted with a -11.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 1.46 million USD, implying an decrease of -10.00% EPS, and increase of 99.62% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Femasys Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Femasys Inc. Common Stock reported EPS of -$0.10, beating estimates by 24.59%, and revenue of $729.00K, -50.71% below expectations.
How did the market react to Femasys Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -11.28%, changed from $0.90 before the earnings release to $0.80 the day after.
When is Femasys Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 25, 2026.
What are the forecasts for Femasys Inc. Common Stock's next earnings report?
Based on 5
analysts, Femasys Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $1.46M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement